Guowei founded Evoclinical with the goal of building a client-centric CRO that remains competitive in the era of Artificial General Intelligence (AGI) and the open-source future of pharmaceuticals. Backed by over ten years of leadership in biostatistics, he has directed multidisciplinary teams through protocol development, regulatory submissions, and full-phase clinical trials across multiple therapeutic areas including oncology and immunology.
As a soon-to-be Ph.D. graduate at McGill University, Guowei’s research leverages registry and real-world data to optimise trial design and enrollment forecasting. This expertise shapes Evoclinical’s data-driven services, where advanced statistical methods and AI tools accelerate decision-making while a robust quality-management system safeguards compliance and builds trust with sponsors and regulators alike.
Guowei is committed on building Evoclinical as being an innovation-driven Contract Research Organization (CRO) that stands at the forefront of the clinical research industry.
“Every time we recommend a statistical approach, we’re not just offering a solution, we’re standing behind it with our name and reputation. Over the years, our team has worked with intention and integrity to ensure that trust and quality are not just promises, but the very foundation of who we are.”